Emphasis laid on continuous medical edu for doctors
The event was inaugurated by Dr Chandrasekhar, Vice-Chancellor of Dr NTR University of Health Sciences, along with Dr D Srihari Rao, Chairman of AP Medical Council.
The dignitaries paid floral tributes to Dr B C Roy, the father of Indian medicine, before lighting the ceremonial lamp.
Dr. Chandrasekhar emphasised the importance of continuous medical education to keep up with advancements in modern healthcare.
Dr Srihari Rao stressed that doctors must renew their medical registration every five years by attending CME programmes and accumulating 30 credit points.
He warned of strict action against unqualified practitioners exceeding their permitted roles.
Dr G Nanda Kishore, IMA State president, highlighted IMA's commitment to public health through over 100 local branches. Organising Chairman Dr. Ravi Krishna and IMA Nandyal President Dr Madhusudhana Rao stated that such conferences greatly benefit regional doctors by enhancing awareness of medical advancements.
Eminent doctors from reputed hospitals like Apollo, Omega Cancer Hospital, and Yashoda Hospital delivered lectures on various health topics, contributing to the academic success of the event.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
14 minutes ago
- Hindustan Times
650 private Haryana hospitals to withdraw Ayushman Bharat services from August 7
Around 650-700 private hospitals in Haryana are set to withdraw from the Ayushman Bharat scheme starting August 7 due to pending dues of over ₹500 crore. Around 650-700 private hospitals in Haryana are set to withdraw from the Ayushman Bharat scheme starting August 7 due to pending dues of over ₹ 500 crore. The Indian Medical Association (IMA) Haryana claimed that despite multiple assurances from government officials, payments continue to be delayed, with some hospitals experiencing delays of up to 4-5 months. Speaking to ANI, former president of Haryana IMA, Dr Ashok Mahajan said, 'IMA Haryana does not want to withdraw Ayushman services; it is being forced to! Hospitals have bills running into crores and are unable to pay their doctors, staff and vendors. They are forced to take this step to prevent further losses. They seem to be funding this government scheme; they pay late, and deductions are made without any reason.' 'Nearly 650-700 private hospitals all over Haryana will withdraw services. Assurances are plenty, but payment is much less! After our protests, the government pays every 3-4 months and then waits for the next protest. Even after assurances from the highest offices in the state, our dues keep on piling up,' he added. According to the letter written by IMA Haryana to the CEO Ayushman Bharat Haryana Health Protection Authority, the scheme is facing several challenges. 'Ayushman Bharat Yojana, a prestigious scheme of Prime Minister Narender Modiji, is facing recurrent problems in Haryana due to the apathy of the government itself. Time and again, we have been apprising officials of irregular payments, at times delayed by 4-5 months.' states the letter. Earlier, a meeting was also held with the Haryana chief minister and other senior officials, but none of the assurances were fulfilled.
The Hindu
an hour ago
- The Hindu
Simpler tests could slash biosimilar costs, widen patient access
Most of the drugs that we consume are called 'small molecule drugs'. Their chemical structure is reasonably simple. Disprin, for instance, has a molecular weight of around 180 daltons. There is another breed of drugs that are very large, complex molecules. For instance, the molecular weight of insulin is around 5,800 daltons and that of the monoclonal antibody remicade, about 150,000 daltons. (One dalton is equal to one-12th the mass of a carbon-12 atom.) Small molecule drugs also tend to have fixed structures that do not change for the duration of their use. In contrast, the complex molecules, which we call biologics, are produced in biological systems and therefore during their production slight variations in the structure may arise. However, these variations may have no impact on the stability of the molecule, its efficacy or its side effects. When a company produces a small molecule drug for the first time, it seeks patent protection for that drug. That is, no competitor may make that drug for several years. It is only when the drug goes 'off patent' that competitors may make it. In the absence of competition, the originator company can price the drug very high. Once there is competition, the competitor companies produce generics, which are copies of the original drug. They don't undertake the research and development to make the drug and they may not spend as much on marketing and sales, so the costs of generics are also much lower. Most of the drugs that you and I take are generics and are priced very cheaply compared to the originator drug. A good example is Sovaldi, a drug used to treat hepatitis C: it originally cost $84,000 for a 12-week course in the US but that dropped to $1,000 once Indian generic firms started making it. Largely it is generic drugs that keep us in India alive and well. Since biologics made by a generic firm will be produced by different biological systems, they may not be identical to those made by the originator company. Thus they are called biosimilars, not generics. For many years, a debate has raged over how much proof is required for a manufacturer to prove that a given biosimilar will work as well as the original biologic drug. Therefore, whereas much simpler testing was required to show that a generic small molecule was working like the originator molecule, there are more elaborate and expensive tests for biosimilars. Major drug regulators such as those of the US, the UK, and in Europe have been working to determine how they can simplify the requirements for approving a biosimilar, in view of the availability of modern analytical techniques. For example, the UK has removed animal trials and the US has planned to replace them with more human-relevant methods (like using organoids). In India, this requirement has not yet been updated although there is a proposal to waive animal studies on a case-by-case basis. Some have also argued that India should follow the practices of the UK and the US. The same holds for the more expensive clinical trials, which in the UK are currently required only in certain cases. Biosimilars need to be made less expensively while ensuring efficacy and minimal adverse effects. The larger the number of affordable biosimilars, the more options we will have for our patients. Gayatri Saberwal is a consultant at the Tata Institute for Genetics and Society.
Time of India
4 hours ago
- Time of India
At PGI, new hope to rein in type-2 diabetes
1 2 Chandigarh: Type 2 diabetes mellitus (T2DM) may not be invincible after all. Researchers are exploring the possibility of achieving remission through a combination of medication and lifestyle changes. The study, 'DiaRem-1' – recently published in the 'Indian journal of endocrinology and metabolism' – challenges the traditional view that T2DM is a permanent condition and provides evidence that remission is a feasible goal for some patients. The DiaRem-1 trial was an open-label, randomised controlled study at a single centre in India. It involved adult patients with T2DM of less than five years duration and an HbA1c level below 8.5% All participants were medicated for three months, followed by a three-month off-treatment period to assess for remission. Remission was officially defined as maintaining an HbA1c below 6.5% without any antidiabetic medication for three months. Nearly a third of the patients achieved remission. This small but powerful trial offers a cost-effective and scalable strategy that can work in outpatient clinics across India and the world. "With early, intensive treatment and continued support, many patients may no longer need diabetes medication. That's a powerful message of hope," said Dr Rama Walia, lead investigator of the study, adding: "Physical workout for an hour daily, including brisk walk, yoga or dance, was advised in the trial. Patients were kept on home-based healthy diet." Unlike other methods that rely on intensive, impractical diets or expensive surgeries, this study focused on using modern, widely available medications along with standard dietary and physical activity advice. Doctors now understand that two major culprits drive diabetes progression: glucotoxicity (too much sugar damaging beta cells) and lipotoxicity (fat accumulation impairing insulin action). By reversing these with medication and lifestyle therapy, the pancreas gets a much-needed break and, in some cases, begins to function more normally again. SWEAT & DIET MAY KEEP PILLS AWAY Chandigarh is considered the diabetic capital of India as the prevalence of prediabetes and diabetes is the highest in the country How Test Was Conducted Participants were divided into two groups: Intervention arm: 14 patients received a combination of liraglutide, dapagliflozin, and metformin. Control arm: 15 patients received vildagliptin, glimepiride, and metformin. Definition of Remission: HbA1c <6.5% for at least 3 months without medication Key Findings Remission Rate: 9 of the 29 participants (31%) achieved remission. Four from the intervention arm and five from control arm maintained HbA1c below 6.5% without treatment Weight Loss: Both groups experienced significant weight loss, as well as reductions in fat mass and body fat percentage. Intervention group had a median weight loss of -4.9 kg and the control group -3 kg, No Special Meds: Both modern and standard drugs helped when tightly managed Hope Floats: Not a cure, but a realistic and hopeful path to freedom from drugs Any Predictors Of Success? No baseline characteristics could be identified to predict which patients would achieve remission. However, those who did achieve remission tended to have a shorter duration of diabetes and greater weight loss. What's Next? PGI team is continuing research to test how long remission lasts and whether longer treatment duration might improve outcomes further Get the latest lifestyle updates on Times of India, along with Friendship Day wishes , messages and quotes !
